[Renal cancer: bone metastases, immunotherapy and interleukin-6].
In renal cell carcinoma, bone metastases remain a major medical challenge because they are refractory to the antiproliferative effects of immunotherapy. We critically review the biological and clinical data which implicate interleukin-6 in the tumor growth, the pathogenesis of the bone metastases and the response to immunotherapy.
Paule
B
B
Service de Rhumatologie, Hôpital de Bicêtre, Le Kemlin-Bicêtre.
Clerc
D
D
D000818:Animals; D017209:Apoptosis; D001859:Bone Neoplasms / Q000235:genetics / Q000276:immunology / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D002292:Carcinoma, Renal Cell / Q000235:genetics / Q000276:immunology / Q000401:mortality; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use; D015850:Interleukin-6 / Q000097:blood / Q000502:physiology*; D007680:Kidney Neoplasms / Q000235:genetics / Q000276:immunology / Q000401:mortality; D051379:Mice; D008819:Mice, Nude; D011379:Prognosis; D019947:Receptors, Interleukin-6 / Q000502:physiology; D015398:Signal Transduction; D013997:Time Factors; D014157:Transcription Factors / Q000502:physiology; D014407:Tumor Cells, Cultured / Q000276:immunology
D007376:Interleukin-2; D015850:Interleukin-6; D019947:Receptors, Interleukin-6; D014157:Transcription Factors